stockrowIncyte Corporation
INCYIncyte Corporation’s revenue for fiscal 2025 (year ended December 2025) was $5.1 billion, up 21.2% from fiscal 2024.
- Revenue
- +14.0%
- EPS
- −277.9%
- Free cash flow
- −233.0%
- Total debt
- −10.5%
Quarter to September 2026, against a year earlier
Follow INCY
Alert me
Incyte Corporation (INCY) Debt to equity
Incyte Corporation's debt to equity at the end of the quarter to 30 September 2026 was 0.0×, down 0.0× from fiscal 2025 (0.0×). Over the past ten years it has ranged from 0.0× (fiscal 2023) to 3.6× (fiscal 2015); the current reading is higher than 18% of that period. That is above the Biotechnology industry median of 0.0× and above the Healthcare sector median of 0.0×.
Debt to equity, annual
Embed this chart
Annual newest first
| Period | Debt to equity | Change |
|---|---|---|
| FY2025 | 0.0× | (40.21%) |
| FY2024 | 0.0× | 73.21% |
| FY2023 | 0.0× | (18.84%) |
| FY2022 | 0.0× | (17.86%) |
| FY2021 | 0.0× | (32.80%) |
| FY2020 | 0.0× | (35.23%) |
| FY2019 | 0.0× | 112.09% |
| FY2018 | 0.0× | (38.10%) |
| FY2017 | 0.0× | (99.05%) |
| FY2016 | 1.6× | (57.12%) |
Quarterly newest first
| Period | Debt to equity | Change |
|---|---|---|
| Sep 2026 | 0.0× | 8.89% |
| Jun 2026 | 0.0× | (13.46%) |
| Mar 2026 | 0.0× | (10.34%) |
| Dec 2025 | 0.0× | (12.12%) |
| 43 more quarters | Free account |
Against its own ten years
Debt to equity against peers
| Company | Debt to equity |
|---|---|
| ROIV Roivant Sciences Ltd. compare | 0.0× |
| EXEL Exelixis, Inc. compare | 0.0× |
| INCY Incyte Corporation | 0.0× |
| BNTX BioNTech SE Sponsored ADR compare | 0.0× |
| ALNY Alnylam Pharmaceuticals, Inc. compare | 0.3× |
| ASND Ascendis Pharma A/S compare | 0.3× |
| INSM Insmed, Inc. compare | 0.8× |
| GMAB Genmab A/S Sponsored ADR compare | 0.8× |
| JAZZ Jazz Pharmaceuticals PLC compare | 1.3× |
| Biotechnology industry median | 0.0× |
| Healthcare sector median | 0.0× |
| Market median | 0.2× |
What Debt to equity is
Debt to Equity Ratio shows how much a company relies on borrowed money compared with the money its shareholders have in the business.
(Long Term Debt (Total) + Current Part of Debt) ÷ Shareholders Equity (Total)
More on INCY
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement